Status:
COMPLETED
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
Lead Sponsor:
Cipherome, Inc.
Collaborating Sponsors:
Stanford University
Conditions:
Acute Lymphoblastic Leukemia, Pediatric
Adverse Drug Event
Eligibility:
All Genders
Up to 21 years
Brief Summary
This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
Detailed Description
The study objective is to clinically validate that the presence of recently discovered novel genetic variation adversely affects a population of 6-mercaptopurine treated pediatric acute lymphoblastic ...
Eligibility Criteria
Inclusion
- Pediatric acute lymphoblastic leukemia (ALL) subjects
- Received 6-mercaptopurine
- Available biobank (bone marrow or blood) sample(s) from which deoxyribonucleic acid (DNA) can be extracted
- White blood cell (WBC) levels
Exclusion
- Pediatric ALL subjects who did NOT receive 6-mercaptopurine
- No biobank sample
- No WBC level
Key Trial Info
Start Date :
February 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 10 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04770922
Start Date
February 23 2021
End Date
November 10 2021
Last Update
February 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94304